X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA NATCO PHARMA ALEMBIC PHARMA/
NATCO PHARMA
 
P/E (TTM) x 16.2 13.2 122.4% View Chart
P/BV x 3.5 2.8 127.8% View Chart
Dividend Yield % 1.1 1.6 67.0%  

Financials

 ALEMBIC PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
NATCO PHARMA
Mar-18
ALEMBIC PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs6641,080 61.5%   
Low Rs412671 61.4%   
Sales per share (Unadj.) Rs208.7592.1 35.3%  
Earnings per share (Unadj.) Rs31.0188.4 16.5%  
Cash flow per share (Unadj.) Rs37.1206.3 18.0%  
Dividends per share (Unadj.) Rs5.508.25 66.7%  
Dividend yield (eoy) %1.00.9 108.5%  
Book value per share (Unadj.) Rs144.2833.6 17.3%  
Shares outstanding (eoy) m188.5236.90 510.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.61.5 174.4%   
Avg P/E ratio x17.44.6 373.6%  
P/CF ratio (eoy) x14.54.2 341.7%  
Price / Book Value ratio x3.71.1 355.3%  
Dividend payout %17.74.4 405.2%   
Avg Mkt Cap Rs m101,46132,311 314.0%   
No. of employees `000NA4.8 0.0%   
Total wages/salary Rs m7,4673,256 229.3%   
Avg. sales/employee Rs ThNM4,522.5-  
Avg. wages/employee Rs ThNM674.0-  
Avg. net profit/employee Rs ThNM1,439.0-  
INCOME DATA
Net Sales Rs m39,34721,848 180.1%  
Other income Rs m94404 23.2%   
Total revenues Rs m39,44122,252 177.2%   
Gross profit Rs m8,7369,284 94.1%  
Depreciation Rs m1,152662 174.1%   
Interest Rs m184154 119.5%   
Profit before tax Rs m7,4938,872 84.5%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5681,920 81.6%   
Profit after tax Rs m5,8446,952 84.1%  
Gross profit margin %22.242.5 52.2%  
Effective tax rate %20.921.6 96.7%   
Net profit margin %14.931.8 46.7%  
BALANCE SHEET DATA
Current assets Rs m19,57721,307 91.9%   
Current liabilities Rs m14,8965,920 251.6%   
Net working cap to sales %11.970.4 16.9%  
Current ratio x1.33.6 36.5%  
Inventory Days Days9073 122.5%  
Debtors Days Days45107 42.6%  
Net fixed assets Rs m27,09714,986 180.8%   
Share capital Rs m377369 102.2%   
"Free" reserves Rs m26,81130,353 88.3%   
Net worth Rs m27,18830,760 88.4%   
Long term debt Rs m4,9930-   
Total assets Rs m47,77837,151 128.6%  
Interest coverage x41.758.6 71.2%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.6 140.0%   
Return on assets %12.619.1 66.0%  
Return on equity %21.522.6 95.1%  
Return on capital %23.629.3 80.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45310,322 188.5%   
Fx outflow Rs m6,0652,978 203.6%   
Net fx Rs m13,3887,343 182.3%   
CASH FLOW
From Operations Rs m8,1204,636 175.1%  
From Investments Rs m-7,556-11,155 67.7%  
From Financial Activity Rs m5906,509 9.1%  
Net Cashflow Rs m1,153-18 -6,407.2%  

Share Holding

Indian Promoters % 74.1 52.0 142.4%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 2.9 7.8 37.0%  
FIIs % 9.1 16.6 54.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 26.0 53.5%  
Shareholders   49,328 25,395 194.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT  AUROBINDO PHARMA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; TCS and Bharti Airtel Top Gainers(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.7% while the Hang Seng is up 1.1%.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 19, 2019 11:31 AM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS